HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Press Releases Hansoh Pharmaceutical Group Company Limited

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 08:09:14 10/02/2026 GMT			5-day change	1st Jan Change
37.54 ^HKD	+1.13%		+0.21%	+4.05%

02-03	Hansoh Pharmaceutical Sells HK$4.68 Billion Convertible Bonds	MT
01-27	Hansoh Pharmaceutical Plans Nearly HK$4.7 Billion Zero-Coupon Convertible Bond Issue	MT

Press Releases

01-12	Hansoh Pharmaceutical : PHARMA \| AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI	PU
12-16	Hansoh Pharmaceutical : PHARMA GRANTS GLENMARK EXCLUSIVE MULTI-REGIONAL RIGHTS REGARDING AUMOLERTINIB	PU
12-11	Hansoh Pharmaceutical : ESMO ASIA \| HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC	PU
12-10	Hansoh Pharmaceutical : ESMO ASIA \| HANSOH PHARMA ANNOUNCES MINI ORAL PRESENTATION OF PHASE 1 STUDY OF RISVUTATUG REZETECAN (HS-20093, A B7-H3-TARGETED ADC) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)	PU
12-08	HANSOH PHARMA: TWO NEW INDICATIONS OF ALMONERTINIB ADDED TO THE 2025 NRDL; MULTIPLE INNOVATIVE DRUGS RENEWED	PU
11-10	Hansoh Pharmaceutical : PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025	PU
23/10/25	Hansoh Pharmaceutical : CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC	PU
20/10/25	Hansoh Pharmaceutical : ESMO 2025 \| Hansoh Pharma Announces Proffered Paper Presentation of Phase 2 Study on HS-20093 (B7-H3-targeted ADC) in Relapsed or Refractory Sarcomas	PU
20/10/25	Hansoh Pharmaceutical : ESMO 2025 \| Hansoh Pharma Presents the phase 2 study findings of HS-20089 (B7-H4-targeted ADC), in patients with platinum-resistant ovarian cancer (PROC)	PU
17/10/25	Hansoh Pharmaceutical : GRANTS ROCHE AN EXCLUSIVE LICENSE TO NOVEL CDH17-TARGETING ADC HS-20110	PU
01/09/25	Hansoh Pharmaceutical : 翰森制药 \| 昕越®第二项适应症获批上市，适用于免疫球蛋白G4相关性疾病成人患者	PU
05/06/25	Hansoh Pharma \| Aumolertinib: Approved by UK’s MHRA for the Treatment of NSCLC — Marking the First Overseas Launch of China-Developed EGFR-TKI	PU
02/06/25	Hansoh Pharmaceutical : PHARMA GRANTS REGENERON AN EXCLUSIVE LICENSE RIGHTS TO ITS INVESTIGATIONAL DUAL GLP-1/GIP RECEPTOR AGONIST HS-20094	PU
31/05/25	Hansoh Pharmaceutical : PHARMA ANNOUNCES THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE(INEBILIZUMAB INJECTION) ACCEPTED BY NMPA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS	PU
09/05/25	Hansoh Pharmaceutical : Pharma \| Ameile's fourth indication approved for marketing, targeting post-operative adjuvant therapy for EGFR mutation-positive non-small cell lung cancer	PU
27/04/25	Hansoh Pharmaceutical : 2024环境、社会及管治报告	PU
27/04/25	Hansoh Pharmaceutical : ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024	PU
15/04/25	Hansoh Pharmaceutical : PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA FOR HS-10529 in advanced solid tumors	PU
24/01/24	2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	AQ
19/10/23	Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award	AQ
25/09/23	Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia	AQ
20/07/23	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China	AQ
27/09/22	KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan	AQ
29/03/22	Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021	PU
12/10/21	Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Hansoh Pharmaceutical Group Company Limited : Regulator grants breakthrough-therapy status to lung cancer drug

December 03, 2024 at 05:31 pm